TCGA-WT-AB44-01A-11R-A41B-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 29
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- TNFA_SIGNALING_VIA_NFKB+0.370
- COAGULATION+0.360
- MYOGENESIS+0.280
- PANCREAS_BETA_CELLS+0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- INFLAMMATORY_RESPONSE+0.170
- P53_PATHWAY+0.170
- KRAS_SIGNALING_UP+0.150
- XENOBIOTIC_METABOLISM+0.120
Top 10 suppressed
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.590
- MITOTIC_SPINDLE-0.540
- PROTEIN_SECRETION-0.440
- MTORC1_SIGNALING-0.380
- MYC_TARGETS_V1-0.340
- INTERFERON_ALPHA_RESPONSE-0.320
- PI3K_AKT_MTOR_SIGNALING-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.250
- ESTROGEN_RESPONSE_EARLY-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-Z7-A8R5-01A-42R-A41B-07 | — | B | 0.891 |
| 2 | TCGA-BH-A42U-01A-12R-A24H-07 | — | B | 0.869 |
| 3 | TCGA-AC-A3QP-01A-11R-A22U-07 | — | B | 0.867 |
| 4 | TCGA-OL-A66N-01A-12R-A31O-07 | — | B | 0.837 |
| 5 | TCGA-FD-A43U-01A-11R-A23W-07 | — | — | 0.818 |
| 6 | TCGA-LD-A66U-01A-11R-A31O-07 | — | B | 0.815 |
| 7 | TCGA-GM-A5PX-01A-12R-A28M-07 | — | A | 0.810 |
| 8 | TCGA-AC-A2QJ-01A-12R-A19W-07 | — | A | 0.810 |
| 9 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.804 |
| 10 | TCGA-B6-A401-01A-11R-A239-07 | — | B | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| HYPOXIA | 0.060 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.060 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.050 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.050 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.040 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |